Control of myogenic tone and agonist induced contraction of intramural coronary resistance arterioles by cannabinoid type 1 receptors and endocannabinoids by Szekeres, Mária et al.
Contents lists available at ScienceDirect
Prostaglandins and Other Lipid Mediators
journal homepage: www.elsevier.com/locate/prostaglandins
Original Research Article
Control of myogenic tone and agonist induced contraction of intramural
coronary resistance arterioles by cannabinoid type 1 receptors and
endocannabinoids
Mária Szekeresa,b, György L. Nádasya,⁎, Eszter Soltész-Katonaa, László Hunyadya,c
a Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
b Department of Morphology and Physiology, Faculty of Health Sciences, Budapest, Hungary
c Laboratory of Molecular Physiology at Semmelweis University, Hungarian Academy of Sciences, Budapest, Hungary
A R T I C L E I N F O
Keywords:
Angiotensin II
Coronary artery
Cannabinoid
Vascular tone
Diacylglycerol
A B S T R A C T
It was tested whether intrinsic CB1R activation modiﬁes myogenic and agonist induced contraction of intramural
coronary resistance arteries of the rat. CB1R protein was detected by immuno-histochemistry and by Western
blot, its mRNA by qRT-PCR in their wall. Microsurgically prepared cylindrical coronary segments
(∼100–150 μm) developed myogenic contraction (∼20% of relaxed luminal diameter), from which a sub-
stantial relaxation (∼15%) in response to WIN55212 (a speciﬁc agonist of the CB1Rs) has been found. CB1R-
mediated relaxation was blocked by O2050 and AM251 (neutral antagonist and inverse agonist of the CB1R,
respectively) and was partially blocked by the NO synthase blocker Nω-nitro-L-arginine. CB1R blockade en-
hanced myogenic tone and augmented AngII-induced vasoconstriction (from 17.8 ± 1.2 to 29.1 ± 2.9%,
p < 0.05). Inhibition of diacylglycerol lipase by tetrahydrolipstatin, (inhibitor of endogenous 2-AG production)
also augmented coronary vasoconstriction. These observations prove that vascular endocannabinoids are sig-
niﬁcant negative modulators of the myogenic and agonist-induced tone of intramural coronary arterioles acting
through CB1Rs.
1. Introduction
Hemodynamic resistance of intramural coronary arterioles with
diameters below 200 μm determines local ventricular ﬂow. Such vessels
have a substantial spontaneous/myogenic tone which is kept reduced
by metabolic factors from surrounding ventricular tissue, beta adre-
nergic eﬀects, endothelial nitric oxide (NO) and also by vasodilatory
prostanoids produced in the wall. Compared to resting coronary vas-
cular ﬂow, during heavy physical exercise and also in hypoxia a 4–5
times increase in cardiac blood ﬂow (“coronary vasomotion”) can be
achieved [1–7].
It has been revealed, that exogenous tetrahydro-cannabinol (THC)
[8], anandamide, 2-arachidonoylglycerol (2-AG) [9,10], diﬀerent nat-
ural and synthetic agonists of the CB1R (e.g. WIN55212) [11–14] cause
substantial vasodilation in several vascular beds, such as in coronary
arteries [9–11], cerebral arteries [11], the mesenteric vascular bed [8]
and in the aorta [14]. Several hemodynamically and clinically im-
portant resistance arteries also responded to cannabinoids [8,15]. Most
vasodilatory and hypotensive actions of cannabinoids seem to involve
the CB1R receptors [11,15,16].
Endocannabinoids are produced in the wall of diﬀerent vessels and
by their vasodilatory actions they contribute to local vascular control
[15–22]. However, the extent of this contribution can be much diﬀerent
in diﬀerent vascular areas [18–24]. Exogenous cannabinoids increased
coronary ﬂow in isolated rodent hearts [25], dilated larger coronary
arteries [9,10,17,26] and even cardioprotective and antiischemic ef-
fects [27–29] have been attributed to them. In an earlier work from our
laboratory [16], we have demonstrated that continuous production of
endocannabinoids (mostly 2-AG) in the wall of skeletal muscle re-
sistance arterioles maintained a reduced spontaneous and agonist in-
duced tone via vascular CB1 receptors. Pharmacological control of
coronary resistance arteries might be much diﬀerent from that of
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resistance arteries in other vascular areas [3] and may even diﬀer from
larger coronary vessels [5]. Myogenic contraction and tone of re-
sistance-sized arteries involves diﬀerent agonist-induced and cellular
mechanisms [30].
Taking into consideration the unique clinical signiﬁcance of the
coronary vascular system and the speciﬁc features of coronary re-
sistance artery control it is of utmost importance to study whether
endocannabinoid-mediated vasodilatory mechanisms do exist in cor-
onary resistance arteries and to what extent they are able to modulate
the myogenic and agonist induced coronary vascular tone.
2. Materials and methods
2.1. Animals
Male Wistar rats were used (250–350 g, Charles River Laboratories-
Semmelweis University, Budapest). All animals were anaesthetized
with pentobarbital sodium (Euthasol, ASTfarma 50 mg/kg in-
traperitoneally) and an extra dose (appr. 10 mg/kg) was additionally
given, if necessary. Anesthetized animals were sacriﬁced by fast
bleeding. The investigation conforms to the Guide for the Care and Use of
Laboratory Animals (NIH, 8th edition, 2011) as well as National legal
and institutional guidelines for animal care. They were approved by the
Animal Care Committee of the Semmelweis University, Budapest and by
Hungarian authorities (No. 263/003/2008 and No. 001/2139-4/2012).
2.2. Chemicals
Angiotensin II (Ang II), bradykinin (BK), WIN55212 (a CB1R ago-
nist), sodium-nitroprusside (SNP), Nω-nitro-L-arginine (LNA, an in-
hibitor of nitric oxide synthase) and tetrahydrolipstatin (THL, a dia-
cylglycerol lipase inhibitor) were purchased from Sigma-Aldrich (St.
Louis, MO, US). The neutral CB1R antagonist O2050, the inverse CB1R
agonist AM251 were purchased from Tocris Bioscience (Elliswille, MI,
US). All other salts and chemicals were purchased from Sigma.
2.3. Immunohistochemistry
Hearts from rats and mice were ﬁxed in 4% paraformaldehyde and
placed in 10 and 20% sucrose solutions (15–18 h each) for cryopro-
tection. The tissues were quickly frozen on dry ice, embedding, sec-
tioning and staining were executed as described [22,31]. Im-
munostaining was performed with CB1R primary antibody (Cayman
Chemicals, Ann Arbor, MI, overnight). The development of slides was
made using the biotin extravidin ABC method (Vector Labs, Burlington,
CA). Diaminobenzidine (DAB) was used for visualization [22,31]. An-
tibody speciﬁcity was conﬁrmed preparing aortic slides of wild and
CB1R −/− knockout mice.
2.4. Western blots
Microdissected samples were washed twice in ice cold phosphate
buﬀer solution (PBS, composition in mM, NaCl 137, KCl 2.7, Na2HPO4
10.1, KH2PO4 1.8, pH 7.4). They were homogenized in glass tubes and
lysed in SDS lysis buﬀer containing 10% merkapto-ethanol and protease
inhibitor cocktails (Sigma-Aldrich). In the lysis buﬀer samples were
sonicated, boiled and centrifuged. Proteins from tissue samples were
separated with SDS-polyacrylamide gel electrophoresis and were
blotted onto the PVDF membrane. Membranes were treated with anti-
bodies against CB1R (Cayman Chemicals) and beta-actin (Sigma-
Aldrich) followed by the treatment with HRP-conjugated secondary
antibodies. Visualization was made with SuperSignal West Pico reagent
(Promega, Madison, WI) and results were quantitatively evaluated with
densitometry.
2.5. RNA extraction and real-time PCR
Vascular tissues were removed by fast and careful microscopic dis-
section for RNA extraction [16]. In anesthesia, the chest was opened,
the heart removed. Intramural coronary arterioles branching from the
left anterior descendent coronary artery were isolated. Vessels were
placed in cold sterile phosphate buﬀer solution (PBS as above). Total
RNA was extracted (RNeasy mini kit, Qiagen) and reverse transcription
was carried out according to the manufacturer’s instructions (Fer-
mentas, Ontario, Canada). Real-time PCR assays were performed on
LightCycler 480 (Roche Applied Science, Indianapolis, IN) with the
SYBR Green method. Primers were designed and synthesized by Sigma-
Aldrich. Cycling conditions were: 10 min preincubation at 95 °C, 45–50
cycles of 95 °C 10 s, 62 °C 5 s and 72 °C 15 s. Fluorescence data in-
cluding melting curves were obtained. For normalization, the glycer-
aldehyde-3-phosphate dehydrogenase (gapdh) housekeeping gene was
used (ENSRNOG00000004253). Eﬃciency for each primer pair was
determined by using serial dilutions of the PCR product. Fold ratios of
gene expression were calculated as follows:
Ratio = E ΔCttargetgene/E ΔCtGAPDH
Ct was calculated by the second derivative method using LightCycler
480 Software. ΔCt is the diﬀerence in Ct values obtained between the
reference and tested samples. Relative messenger RNA levels of can-
nabinoid receptor type 1 (Cnr1) were calculated
(ENSRNOG00000008223). Primers were for Cnr1: forward primer
GGACTCAGACTGCCTGCACA, reverse primer ACAAAAGCAGCAG
GCTCACA and for gapdh: forward primer CCTGCACCACCAAC
TGCTTAG, reverse primer CAGTCTTCTGAGTGGCAGTGATG. Tissue
gene expression levels were plotted against gapdh expression level.
2.6. Isolation of rat coronary resistance arteries for video
microarteriography
During anaesthesia of rats, the chest was quickly opened, the heart
removed and placed into cold normal Krebs-Ringer (nKR) solution
which contained in mM, NaCl 110, KCl 5.0, CaCl2 2.5, MgSO4 1.0,
KH2PO4 1.0, NaHCO3 24 and glucose, 10 (pH 7.4). Intramural coronary
arterioles branching from the left anterior descending (LAD) coronary
artery were isolated by careful microdissection as described previously
[5,32,33]. Distal segments close to the apex with approximately
100–150 μm of inner diameter were prepared. One segment was pre-
pared and measured from each animal. The segment was placed in a
tissue bath ﬁlled with Krebs solution. It was cannulated at both ends
with microcannulas, extended to its in situ length in the glass bottomed
tissue bath of a pressure microarteriography chamber (Experimetria,
Budapest). Clotted blood was washed out at low perfusion pressure, and
then one of the cannulas was closed. Utilizing a pressure-servo syringe
reservoir system (Living Systems, Burlington, VT, US) arterioles were
pressurized in a no-ﬂow condition. Vessels were checked for leaks by
the stability of the inlet pressure when the servo function was turned
oﬀ. Vessels with observable leaks were discarded. The temperature of
the chamber was maintained at 37 °C, bubbled with 21% O2 and 5%
CO2, balanced with N2, the pH was kept at 7.4. A continuous super-
fusion of the bath was applied at a rate of 2.5 mL/min. The cannulated
vessel was visualized by video-microscopy and the inner diameter was
measured on frozen images (Leica inverted microscope, Leica DFC 320
digital camera, LeicaQWin software) [5,6,16,32]. Calibration was made
with a micrometer etalon (Wilde, Heerbrugg, Switzerland). In-
traluminal pressure was calibrated with a mercury manometer.
2.7. Experimental protocols of isolated vessel studies
Following a 60-min equilibration period, at 50 mmHg intraluminal
pressure in nKR solution, pharmacological responses of the arterial
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segments were tested according to the speciﬁc protocols. Agonists were
administered in a dose-dependent manner into the chamber and steady-
state diameter was recorded for each dose or in a single (submaximal)
dose. 10-min washout periods were applied between drugs. Inhibitors
were applied for at least 10 min prior to and during agonist adminis-
tration. Each inhibitor was applied in separate experimental series, ei-
ther the pressurized segments were in spontaneous myogenic contrac-
tion or their contraction was enhanced with Ang II. In coronary vessels,
Ang II is suitable to produce precontraction, since it produces a stable
contraction without observable desensitization response in contrast to
other type of vessels like gracilis arterioles and aorta [16,22]. After Ang
II precontraction (1 μM), SNP (1 μM) was applied to test endothelium-
independent vasodilation. Endothelial relaxation was tested by brady-
kinin (100 nM), which is an appropriate endothelium-dependent vaso-
dilator in coronary resistance arteries of rats [5]. The experiments were
terminated by obtaining passive (relaxed) vascular diameter in calcium-
free Krebs solution.
In the ﬁrst group of experiments (n = 14), rat coronary arterioles
were subjected to elevated doses of agonists, Ang II (0.1 nM–10 μM),
WIN55212 (0.1 nM–1 μM), SNP (0.1 nM–10 μM) and BK (0.1 μM) with
the CB1R neutral antagonist O2050 (1 μM) or only its vehicle being
present in the bath. Since WIN55212 is lipid-soluble, it was applied
prior to and after CB1R antagonist in separate vessel segments. In the
second group (n = 5), concentration-response to Ang II was obtained
before and during the administration of the DAG lipase inhibitor tet-
rahidrolypstatin (1 μM) or its vehicle. In a third experimental set
(n = 6), the eﬀect of CB1 receptor antagonist (inverse agonist) AM251
(1 μM) (or its vehicle) on the tone of coronary arterioles and on
WIN55212- and SNP-induced vasodilations were tested. In a ﬁfth set of
experiments (n = 5), the eﬀect of Nω-nitro-L-arginine (an inhibitor of
nitric oxide synthase, 50 μM) was applied 20 min prior and during the
administration of CB1R agonist WIN55212 (1 μM) or the endothelium-
dependent agonist BK (0.1 μM) in order to test the role of NO in the
CB1R-mediated coronary functions.
2.8. Statistical analysis
Data are presented as means ± SEM. Vascular tone was calculated
as percent change from passive diameter. Changes in vascular diameter
were also calculated as percent change from control value. For paired
data we used the Student’s t-test, for multiple comparisons one-way and
two-way ANOVAs were applied (SigmaStat). Concentration-response
curves without and with inhibitors present in the solution were com-
pared using the four parameter logistic function (SigmaPlot). Relative
gene expression levels were plotted against reference control (gapdh).
P < 0.05 was considered signiﬁcant for each comparisons.
3. Results
3.1. Molecular and functional evidence of the expression and presence of
CB1Rs in intramural coronary resistance arteries
CB1R protein is present in the wall of these rodent microvessels as it
has been demonstrated by immunohistochemistry of ventricular tissue.
Immunostaining appeared in the wall of intramural coronary arterioles
(Fig. 1A). Western blots also proved the expression of the CB1R protein
in the wall of rat small coronary arteries isolated by microdissection
(Fig. 1B). In addition, messenger RNA for CB1 receptors was also de-
tected by qRT-PCR in amounts similar to those found in rat aortic tissue
(Fig. 1C). Segments in myogenic contraction relaxed in response to the
CB1R agonist WIN 55212 (1 μM). Further, this relaxation could be in-
hibited by the speciﬁc blockers O2050 (1 μM), and AM251 (1 μM).
These CB1R antagonists, however, did not aﬀect either endothelium
independent (SNP, 1 μM) or endothelium dependent (BK, 0.1 μM) re-
laxations (tested on Ang II precontracted segments, Fig. 1D,E).
3.2. Evidence of existence of an intrinsic CB1R activation during
spontaneous myogenic contraction
Coronary arteries when pressurized, exhibit a substantial sponta-
neous, myogenic tone in oxygenized nKR solution. This, with all
probability mimics the in vivo situation [5,32,33]. We tested whether a
basal endocannabinoid release aﬀects the spontaneous tone in these
vessels. Vascular diameter of our segments during spontaneous con-
traction (following an equilibration period) was 138.7 ± 6.6 μm
(inner diameter) corresponding to 20.1 ± 2.9% (n = 15) myogenic
tone (compared with relaxed controls).
The neutral CB1 receptor antagonist (O2050, 1 μM) moderately
(2.6 ± 1.7%, n.s.), the inverse CB1R agonist AM251 (1 μM) sig-
niﬁcantly increased coronary myogenic tone (6.0 ± 1.0%, p < 0.05).
The DAG lipase enzyme inhibitor THL (1 μM) eﬀectively increased
basal coronary tone (11.2 ± 3.9% contraction, p < 0.05). This eﬀect
was additive with the similar eﬀect of AM251: a substantial diameter
reduction of 24.6 ± 5.3% (p < 0.05) was reached when both
Fig. 1. Molecular and functional evidence of the
presence of the CB1R in the intramural coronary re-
sistance arterioles of the rat. (A) Immuno-histo-
chemical localization of CB1R receptors. DAB
staining for CB1R protein. Cross section of an in-
tramural coronary arteriole with strong reaction is
shown. Scale bar shows 100 μm. (B) Western blot of
CB1R protein from homogenates of microsurgically
isolated resistance artery specimens. (C) Expression
of mRNA for CB1R in coronary resistance artery
specimens (CA) and in the aorta (AO) of rats as de-
termined by qRT-PCR (n = 5). Expression fold vs.
gapdh houskeeping gene is plotted. (D, E) Relaxation
in response to CB1R agonist (WIN55212, 1 μM), in-
hibition of relaxation by the speciﬁc CB1R antago-
nists O2050 and AM251 (1 μM) of Ang II-pre-
contracted coronary artery segments. SNP-induced
(1 μM, an endothelium independent vasodilator,
n = 11) and bradykinin-induced (BK, 0.1 μM, an
endothelium dependent coronary vasodilator) vaso-
dilations were not aﬀected by CB1R antagonists
(segments precontracted with 1 μM Ang II, n = 8).
Mean ± SEM values are shown. *, P < 0.05 be-
tween control and inhibitor-treated values.
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antagonists were applied together (Fig. 2.). Products of the enzyme
DAG lipase must be the main endocannabinoids in this tissue. These
experiments indirectly prove that spontaneous myogenic tone of these
vessels is kept under continuous control by endogenously produced 2-
AG. This control can be considered fairly eﬀective as the myogenic
contraction of these vessels practically doubles if 2-AG synthesis and
endocannabinoid action on CB1Rs are both inhibited at the same time.
3.3. Eﬀect of exogenous cannabinoid on coronary arterial tone
Adding angiotensin II to the bath further contracts coronary ar-
teries, this contraction is added to the myogenic tone. The speciﬁc CB1R
agonist WIN55212 very eﬀectively relaxed coronary arteriole segments
precontracted with close-to-maximal concentrations of Ang II (1 μM).
The concentration-dependent vasodilation by the CB1R agonist WIN
55212 is shown on Fig. 3A and C, which is eﬀectively inhibited by the
CB1R antagonists O2050 and AM251. This record proves that agonist
induced contraction of coronary resistance arterioles can be inhibited
by exogenous stimulation of the cannabinoid receptors. However, the
concentration-dependent vasodilation by the NO donor sodium ni-
troprusside (SNP) was not aﬀected by these CB1R antagonists (Fig. 3B
and D). Fig. 3. and Fig. 1D demonstrate an interesting fact: WIN55212,
a CB1R agonist is an almost as eﬀective a coronary vasodilator as the
well-known NO donor SNP is.
3.4. Agonist induced contraction goes on with parallel CB1R activation
Ang II elevated coronary arteriole tone in a dose-dependent manner,
at maximal concentrations inducing about a 20% further reduction of
diameter of segments in spontaneous contraction. This eﬀect reached a
maximum level around 10 μM of Ang II concentration. Inhibition of CB1
receptors by O2050, signiﬁcantly enhanced Ang II-induced contractions
of coronary arterioles (signiﬁcant over 100 nM Ang II, p < 0.05,
Fig. 4). The four parameter logistic analysis has shown that there was
not signiﬁcant change in log EC50% values for Ang II contraction
(−7.36 ± 0.19 vs. −7.54 ± 0.21 without and with the antagonist,
respectively, n.s.), while maximum contraction values signiﬁcantly
elevated (17.8 ± 1.2 vs. 29.1 ± 2.9%, p < 0.05). These
Fig. 2. Intrinsic CB1R activity keeps myogenic tone reduced. The type 1 cannabinoid
receptor (CB1R)-antagonists O2050 (a neutral antagonist, 1 μM) and AM251 (an inverse
agonist, 1 μM) and also the diacylglycerol (DAG) lipase-inhibitor tetrahydrolypstatin
(THL, 1 μM, inhibits the production of 2-AG) substantially increase the spontaneous tone
of pressurized rat coronary arteries (n = 5 or 6 for each group). Mean ± SEM values are
shown. *, P < 0.05 between control and inhibitor-treated values.
Fig. 3. CB1R-mediated modulation of agonist-in-
duced contraction. (A) Concentration dependent di-
lation of Ang II (1 μM) precontracted coronary ar-
teriole segments in response to diﬀerent
concentrations of the CB1R agonist WIN55212. The
relaxation is almost completely inhibited in the pre-
sence of the speciﬁc CB1R blocker O2050 (1 μM,
n = 5–6). (B) For comparison, concentration-depen-
dent vasodilation eﬀect of NO donor sodium ni-
troprusside on coronary artery segments, which was
not aﬀected by the CB1R antagonist treatment
(n = 6–8). (C and D) Similar responses were detected
with the CB1R inverse agonist AM251 (1 μM,
n = 6–8). *, P < 0.05 between control and in-
hibitor-treated values.
Fig. 4. CB1R-mediated modulation of agonist-induced contraction. Enhancement of
concentration dependent Ang II contraction in the presence of the cannabinoid receptor
(CB1R) antagonist O2050 (1 μM) in the tissue bath (n = 10 and 8). *, P < 0.05 between
control and inhibitor-treated values.
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observations prove that during agonist induced contraction, a con-
tinuous and stimulated endocannabinoid production is present in the
wall which modulates contraction due to its eﬀect on CB1Rs.
3.5. Eﬀect of inhibition of DAG lipase enzyme on the agonist-induced
response
The DAG lipase blocker THL also augmented Ang II-induced con-
tractile response in the coronaries (Fig. 5, p < 0.05 at 1 nM–100 nM of
Ang II). The diﬀerence in Ang II-induced contraction with and without
THL reached 5% of diameter at 10 nM Ang II concentration. Based on
this observation, it is highly probable that 2-AG is the endocannabinoid
whose production is elevated by Ang II in this vascular preparation and
the co-stimulation of CB1Rs produced limits then Ang II contraction
[22].
3.6. Role of endothelial nitric oxide in CB1R induced coronary vasodilation
The coronary dilatory eﬀect of the CB1R agonist Win 55212 on Ang
II precontracted segments was partially suspended by the NO synthase
blocker Nω-nitro-L-arginine (50 μM), suggesting a partially NO medi-
ated eﬀect (Fig. 6, p < 0.05). By comparison, the dilatory eﬀect of
bradykinin, an endothelial coronary vasodilator, was fully diminished
by the same concentration of LNA (p < 0.001).
4. Discussion
4.1. Substantial modulator eﬀect found both in myogenic and in agonist
induced contraction
Our observations demonstrated the existence and a substantial
functional role of CB1Rs in rodent intramural coronary arterioles, ves-
sels that basically determine local ventricular ﬂow. The presence of
CB1R protein (with immune-histochemistry and Western blot, Fig. 1A
and B) and of its mRNA (Fig. 1C) have been ﬁrst proven in this vessel-
type. We have also proved that endocannabinoids acting on such re-
ceptors play an important role in forming myogenic and agonist in-
duced tone of these vessels. The speciﬁc CB1R agonist WIN55212 in-
duced a substantial concentration-dependent vasodilation (Fig. 3A and
C) which was prevented by the CB1R neutral antagonist O2050
(Fig. 3A) and by the inverse agonist AM251 (Fig. 3C). AM251 and the
DAG lipase enzyme inhibitor THL substantially increased coronary ar-
teriole myogenic tone (Fig. 2). Ang II induced tone was augmented both
by O2050 and THL (Figs. 4 and 5). We have a sound foundation to
declare that a DAG lipase product endocannabinoid, with all prob-
ability 2-AG is continuously synthesized in the wall of these vessels, and
the amount produced is enhanced by Ang II. Both the spontaneous
myogenic and Ang II-induced contractions are attenuated by its eﬀect.
As neither SNP nor BK relaxations were eﬀected by CB1R antagonists
(Fig. 1E, Fig. 3B and D), we can conclude that simply altering the
contractile state of a coronary arteriole segment will not automatically
alter its endocannabinoid production.
4.2. Coronary cannabinoid-mediated relaxation
Our ﬁndings are in accord with an earlier publication by White et al.
[9] who found that isolated rings prepared from the left anterior des-
cendent coronary artery of the rat (not a resistance sized artery) and
precontracted with 5-HT, dilated in response to exogenous anandamide.
This dilation could be inhibited by the CB1R blocker SR141716A. It is
interesting to note that they have found the more speciﬁc CB1R blocker
AM251 less eﬀective. There seems to be some contradiction also with
the observations by Mair et al. [26]. On main coronary artery branches
of the rat, precontracted with U46619 (a thromboxane agonist), they
have found that relaxation occurred through CB2Rs due to activation of
the ERK1/2 pathway and vasodilatory prostanoids. Our opinion is that
tissue composition and function of larger coronary arteries viable for
wire myographic studies can be substantially diﬀerent from the real
resistance vessels studied by us using the pressure arteriography tech-
nique.
4.3. Coronary endocannabinoid production and relaxation
Endocannabinoid production has been detected in diﬀerent vascular
beds and also in heart [15–22]. Several types of cells of diﬀerent vas-
cular tissues can be sources of endocannabinoids: endothelial cells,
smooth muscle cells, perivascular neurons, platelets, leukocytes,
monocytes, macrophages etc. [18,34–36]. Endogenous release of 2-AG
has been observed from human vascular endothelial cells. The 2-AG
released was supposed to be an intrinsic vasomodulator [37]. In bovine
coronary arteries, metacholine stimulates endothelial 2-AG release
through PLC and DAGL activation and serves as an intermediate for
vasodilatory eicosanoid release [34]. Not only endothelial cells but also
vascular smooth muscle cells can release 2-AG [22]. We have found
previously that Ang II-stimulated 2-AG-release from vascular smooth
muscle cells has been attenuated by the inhibition of DAG lipase and
augmented by monoacylglycerol (MAG) lipase inhibition [22]. In con-
formity with the vascular production of 2-AG, we have also found that
inhibition of DAG lipase augmented, while inhibition of MAG lipase
attenuated vasoconstriction of the aorta. This indicates the role of lo-
cally released 2-AG in the control of vascular tone in this vessel [22].
Similarly, a previous observation found that 2-AG production in rat
aorta was enhanced by carbachol [38].
The contribution of the endocannabinoid mechanism to lumen
control in these important vascular segments is substantial, we have a
good reason to suppose a physiological impact. We have found here
that inhibition of DAGL, the enzyme responsible for the production of a
substantial part of tissue endocannabinoids, augmented coronary re-
sistance artery tone by around 10% even without adding any stimu-
lants. The double inhibition of the endocannabinoid eﬀect (both CB1R
and DAGL inhibition) induces 24.6 ± 5.3% contraction, that
Fig. 5. Identiﬁcation of the vasodilatory eﬀect of a diacylglycerol lipase product.
Enhancement of concentration-dependent Ang II-induced contraction in the presence of
the DAG lipase blocker tetrahydrolipstatin (THL, 1 μM) in the tissue bath (n = 6 and 5).
*, P < 0.05 between control and inhibitor-treated values.
Fig. 6. Endothelial component of CB1-R vasodilation. The CB1R agonist WIN55212
(1 μM)-induced vasodilation was partially blocked by the presence of Nω-nitro-L-arginine
in the bath (50 μM, n = 5). For comparison, the full inhibition of BK induced relaxation
by LNA is demonstrated to the right. Mean ± SEM values are shown. *, P < 0.05 and
*** P < 0.01 between control and inhibitor-treated values.
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practically doubles the approximately 20% spontaneous myogenic tone
(Fig. 2). We can conclude that similarly to endogenous prostanoids and
NO, a continuous production of vasodilatory endocannabinoids in the
resistance artery wall counterbalances the myogenic tone in coronary
resistance arteries. The concentration-dependent Ang II-induced con-
traction of these segments has also been accompanied by a stepwise
elevation of the moderating eﬀects of endogenous cannabinoids. Both
the CB1R antagonist O2050 and the DAG lipase blocker THL augmented
Ang II-induced contraction when compared with contraction without
the antagonist (Figs. 4 and 5). This makes it highly probable, that
“basal” endocannabinoid release (and its vasorelaxation eﬀect) is in-
creasing with increasing concentrations of the contracting agonist.
According to a previous observation from our laboratory, in non-
vascular cells co-expressing type 1 angiotensin receptor (AT1R) and
CB1R, Ang II-induced stimulation of AT1Rs via the activation of PLC and
DAG-production led to the transactivation of CB1 receptors by en-
docannabinoid release [39]. The Ang II-induced CB1 receptor activity
was inhibited by DAGL inhibitor suggesting, that 2-AG production from
DAG plays an important role in the mediation of this action [40]. Si-
milarly, our previous observation on skeletal muscle arterioles in-
dicated that inhibition of CB1 receptors augmented Ang II-induced va-
soconstriction by increasing both eﬃcacy and the potency of the Ang II-
induced responses [16].
Considering the mechanism of this relaxing eﬀect, our present stu-
dies on coronary arterioles suggest a mechanism analogous that found
in skeletal muscle arterioles. The AT1R, Gq, PLC, DAG pathway pro-
duces a substrate for the DAG lipase, the 2-AG produced co-activates
CB1Rs in the neighborhood, inducing, by a not fully identiﬁed yet ac-
tion, relaxation, limiting the contraction exerted. How does the co-ac-
tivation of CB1Rs relax these vessels? K+ channel-mediated cell hy-
perpolarization [9,10,17,41], depression of Ca2+ inﬂux [41,42],
modulation of endogenous prostanoid production [9,10,26,35], acti-
vation of Gi/o or other G proteins [3,9,40] are the mechanisms sug-
gested in the literature by diﬀerent authors.
The role of endothelium and endothelium-mediated nitric oxide in
the cannabinoid-induced vasodilatory response seems to be diﬀerent in
diﬀerent vascular territories. Previously, in gracilis arterioles we found
that WIN55212-induced vasodilation was not attenuated by the blocker
of NO synthase nitro-L-arginine, while it eﬀectively inhibited acet-
ylcholine-induced vasodilation [16]. Also, we found that the removal of
endothelium did not change the augmented vasoconstrictor eﬀect in-
duced by the CB1R blocker O2050 in gracilis vessels. Sources of vas-
cular endocannabinoids can be heterogenous: 2-AG production has
been detected both from endothelial cells and from vascular smooth
muscle cells [22,35,37,38]. These observations are in good accordance
with our present observations on coronary resistance vessels, inhibition
of NO synthesis caused a partial (by approx. 50%) attenuation of the
CB1R agonist WIN55212-induced vasodilation.
4.4. Potential physiological role
We can remark here that such intrinsic “braking” feed-backs fre-
quently occur in complex physiological control networks. In case of the
coronary resistance artery control mechanisms, the endothelial NO and
endogenous prostanoid production, stimulated by agonists, can be
mentioned. We and other laboratories have also found earlier that
myogenic and agonist-induced tone of coronary resistance arteries are
ﬁne-tuned by altered NO and vasoactive prostanoid production occur-
ring in the wall of these vessels [3,6,7]. Now, we can add to this a
similar new mechanism: endogenous cannabinoid production. One can
theorize on the potential physiological beneﬁts: Full contraction closing
the lumen can be prevented by them or, certain contractile eﬀects can
be neutralized. Anyway, they yield a more complex and more versatile
lumen control mechanism, which is able to respond to diverse physio-
logical needs in a more diverse manner.
5. Conclusion
Our studies have proven the existence of the CB1R protein, its
mRNA and also its functional relevance to induce substantial vasodi-
lation in the wall of intramural coronary resistance arteries, vessels that
basically determine ventricular local ﬂow. Further, we provide clear
evidence that a vasorelaxant endocannabinoid system is present in
these vessels, which substantially contributes to the physiologically
important lumen controlling mechanisms here through vascular CB1
receptors. This mechanism is active both during spontaneous myogenic
contraction and also in Ang II-induced contraction. We suggest, that to
the known physiological mechanisms that reduce the substantial
spontaneous/myogenic tone of coronary resistance vessels (metabolic
factors, beta adrenergic stimuli, vasodilatory prostanoids and en-
dothelial NO) the endogenous cannabinoids should be added.
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